Curated News
By: NewsRamp Editorial Staff
January 27, 2025
Avant Technologies to Fund Ainnova's FDA Clinical Study for Vision AI Platform
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- Avant Technologies, Inc. and Ainnova Tech, Inc. secure FDA interactions funding for early disease detection through Vision AI, gaining a competitive edge in healthcare tech.
- Ainnova will request pre-submission FDA meeting for clinical testing guidance on Vision AI platform, leading to FDA 510(k) submission for marketing approval.
- Ainnova's innovative AI technology aims to prevent blindness and detect early diabetes, revolutionizing healthcare with proactive solutions for a healthier tomorrow.
- Ainnova's acquisition of exclusive licensing rights for four algorithms offers exciting potential for early detection of cardiovascular risk, diabetes, fatty liver disease, and chronic kidney disease.
Impact - Why it Matters
This news matters as it highlights advancements in AI technology for early disease detection and the crucial role of FDA interactions in bringing innovative healthcare solutions to market. The success of Ainnova's FDA meetings could pave the way for groundbreaking technology to combat various health conditions effectively.
Summary
Avant Technologies, Inc. and partner Ainnova Tech, Inc. announce funding for FDA interactions regarding the Vision AI platform for early disease detection. Ainnova to seek FDA guidance on clinical testing for diabetic retinopathy detection, with plans for 510(k) submission.
AAC, the joint venture of Avant and Ainnova, holds licensing rights for the technology portfolio in the U.S. Ainnova to submit Pre-Sub application for FDA meeting to discuss clearance for algorithms focusing on cardiovascular risk, prediabetes, fatty liver disease, and chronic kidney disease.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Avant Technologies to Fund Ainnova's FDA Clinical Study for Vision AI Platform
